title: Therapeutic effects of high-dose intravenous prednisolone in methanol-induced toxic optic neuropathy.
abstract: OBJECTIVE
  We evaluated the effects of high-dose steroids for the treatment of methanol optic neuropathy.
  
  
  METHODS
  In an interventional case series, 6 patients with a history of sudden visual loss after an ingestion of homemade alcoholic beverages were included in the study. The patients received 250 mg intravenous methyl prednisolone every 6 h for 4 days and continued with oral prednisolone at 1 mg/kg for 10 days. Best-corrected visual acuity (BCVA), optical coherent tomography, fundus photo, and a complete ophthalmologic exam of the patients were taken before the treatment and 3 months after treatment.
  
  
  RESULTS
  All the patients were male. The mean age was 26.34±2.7 years. The mean BCVA before the treatment was 0.86±0.08 in the right eye and 0.93±0.1 in the left eye using the logMAR scale. Four patients showed nerve fiber layer edema as a white density in peripapillary area. After treatment, the mean BCVA was 0.33±0.18 in the right eye and 0.29±0.2 in the left eye using the logMAR scale. The differences between before treatment and after treatment were significant (P=0.008 and P=0.003, respectively). The mean macular thickness and cup.to.disc ratio were unchanged.
  
  
  CONCLUSIONS
  Intravenous high-dose methyl prednisolone may have benefits in the treatment of methanol optic neuropathy.
authors.affiliation: Eye Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Majid
authors.initials: M
authors.lastname: Abrishami
authors.forename: Mohammad
authors.initials: M
authors.lastname: Khalifeh
authors.forename: Moussa
authors.initials: M
authors.lastname: Shoayb
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Abrishami
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000434:Alcoholic Beverages / Q000009:adverse effects / Q000032:analysis; D004632:Emergency Medical Services; D005506:Food Contamination; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D000432:Methanol / Q000097:blood / Q000633:toxicity*; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020258:Neurotoxicity Syndromes / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009901:Optic Nerve Diseases / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012997:Solvents / Q000032:analysis / Q000633:toxicity; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D005938:Glucocorticoids; D018696:Neuroprotective Agents; D012997:Solvents; D011239:Prednisolone; D008775:Methylprednisolone; D000432:Methanol